NCT01923428View on ClinicalTrials.gov

The Efficacy of AZD1722 in Constipation Predominant Irritable Bowel Syndrome (IBS-C)

PHASE2/PHASE3CompletedINTERVENTIONAL
Enrollment

356

Participants

Timeline

Start Date

August 31, 2013

Primary Completion Date

October 31, 2014

Study Completion Date

October 31, 2014

Conditions
Constipation Predominant Irritable Bowel Syndrome
Interventions
DRUG

AZD1722

DRUG

Placebo

Trial Locations (4)

Unknown

Boulder

Greensboro

Winston-Salem

Chattanooga

Sponsors

Lead Sponsor

Ardelyx
All Listed Sponsors
lead

Ardelyx

INDUSTRY